Bruise

Why luck plays such a big role in hockey

Retrieved on: 
Thursday, April 18, 2024
Finger, Bruise, NHL, Baseball, Ice, NBA, Hockey, Probability, Travel, Football, Sport, Sports equipment

In the NHL, it is estimated that the contribution of luck to a team’s season record is approximately 53%.

Key Points: 
  • In the NHL, it is estimated that the contribution of luck to a team’s season record is approximately 53%.
  • The more chances a team has, the less luck plays a role in the outcome.
  • Luck plays much more of a role when the opportunities to score are lower.
  • Deflect, deflect, deflect
    The outsize role of luck in hockey can also be explained by an additional factor.

Orphan designation: Autologous CD34+ cells transduced with a lentiviral vector encoding glucosylceramidase beta Treatment of Gaucher disease, 21/08/2020 Positive

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Brain, B cell, Gaucher's disease, Cell, CD34, Bone marrow, Bleeding, Disease, Seizure, Bruise, Patient, Committee, Knowledge, Fracture, Spleen, Regulation, Fatigue, Autotransplantation, EMA, IRIS, Human, Life expectancy, Eye, Bone pain, Anemia, European, COMP, Sponsor, European Commission, Safety, PPD, Marketing, Liver, Medicine, Pharmaceutical industry

Orphan designation: Autologous CD34+ cells transduced with a lentiviral vector encoding glucosylceramidase beta Treatment of Gaucher disease, 21/08/2020 Positive

Key Points: 


Orphan designation: Autologous CD34+ cells transduced with a lentiviral vector encoding glucosylceramidase beta Treatment of Gaucher disease, 21/08/2020 Positive

RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury

Retrieved on: 
Wednesday, March 20, 2024
OTC Markets Group, Neurogenic bladder dysfunction, Death, Ampakine, DOI, Tetraplegia, Rat, Incidence, Bourbeau, Risk, Bruise, Patient, Research, University, Bladder cancer, Quality of life, Pleasure, EMG, Alom, Catheter, AMPA, Injury, Interim, CSO, Bangladesh Technical Education Board, Urinary tract infection, Respiration, Animal, Kidney, SCI, Rana, RespireRx

Restoration of bladder function is ranked as one of the highest priorities by individuals with SCI (Bourbeau et al., Spinal Cord 58:1216–1226; 2020).

Key Points: 
  • Restoration of bladder function is ranked as one of the highest priorities by individuals with SCI (Bourbeau et al., Spinal Cord 58:1216–1226; 2020).
  • Current treatment approaches usually require interventions such as catheterization for urinary voiding, which have their own set of risks and potentially significant set of complications.
  • The present paper, entitled “Acute ampakines increase voiding function and coordination in a rat model of SCI” (Rana, Alom et al.
  • We believe that this research has the potential to represent a novel, breakthrough in the treatment of SCI, which is badly needed.”

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 13, 2024
Research, Hypersensitivity, Glucose, Deafness, Congestion, Ascites, Furosemide, Cerebral edema, Growth, Edema, Kidney, Ototoxicity, Diuresis, Tinnitus, Bruise, New Drug Application, Patient, Coma, Oliguria, History, NYHA, NDA, Benign prostatic hyperplasia, IDN, Blood volume, Embolism, Insurance, Thrombosis, Trial of the century, Heart failure, Investment, CO2, Urine, Dehydration, Creatinine, Urinary retention, Erythema, Pharmacy, Chronic kidney disease, Organic acid, Patent, Hypoproteinemia, Internationalized domain name, BUN, Huber loss, FDA, Government, GTN, Cirrhosis, Hepatic encephalopathy, Azotemia, Uric acid, Anuria, Pharmaceutical industry

BURLINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the fourth quarter and full-year ended December 31, 2023, and provided a business update. 

Key Points: 
  • Product revenues were $6.1 million, and cost of product revenues were $1.8 million for the fourth quarter of 2023.
  • Research and development expenses were $3.3 million for the fourth quarter of 2023, compared to $2.3 million for the fourth quarter of 2022.
  • Selling, general and administrative expenses were $16.2 million for the fourth quarter of 2023, compared to $7.2 million for the fourth quarter of 2022.
  • scPharmaceuticals reported a net loss of $13.8 million for the fourth quarter of 2023, compared to $9.2 million for the fourth quarter of 2022.

Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Hypersensitivity, Pregnancy, Wart, Head, Congress, Recombinant, Multiple endocrine neoplasia, Dizziness, Safety, Vain, Headache, Bruise, Public, Syncope, Ageing, Merck & Co., Cervical intraepithelial neoplasia, Vulvar intraepithelial neoplasia, Anal cancer, Virus-like particle, Observation, CIN, Thigh, Human, HPV, Plant, Vaginal intraepithelial neoplasia, Nausea, MRK, VLP, Investment, Immunity, Fever, Erythema, Vaccination, Injury, Vaccine, Allergy, Itch, AIN, Swelling

Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.

Key Points: 
  • Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • The latest addition to the pipeline employs the company’s proprietary virus-like particle (VLP) technology to incorporate additional VLPs for expanded HPV type coverage.
  • These randomized, double-blind, multi-year clinical trials will examine the short and long-term efficacy and immunogenicity of a single-dose of GARDASIL 9 versus the currently approved three-dose regimen.

Distinctive Dermatology Introduces Cutting-Edge Technology to Reverse Aging Without Pain or Downtime

Retrieved on: 
Wednesday, April 3, 2024
Skin care, Elastin, Face, Hyaluronic acid, Lifting, Bruise, Patient, Artificial intelligence, Skin, Collagen, Needle, Ageing, Medical imaging

Data shows for most effective results in reducing wrinkles, lifting muscles, and improving facial tone, patients need four treatments of EMface -- one per week.  Optimal results are noticeable 6 to 12 weeks after four treatments.

Key Points: 
  • ST. LOUIS, April 3, 2024 /PRNewswire/ -- Distinctive Dermatology , a leading St. Louis-area dermatology practice, is the first to offer groundbreaking technology that reverses aging and reduces wrinkles without discomfort, needles, or downtime.
  • The clinic is hosting "Hello Spring," a complimentary beauty/makeover event on April 11 for those who want to try it.
  • "EMface is the wave of the future for those wanting to reverse aging," says Angela Sutton, D.O.
  • Distinctive Dermatology provides medical and surgical care to patients with skin conditions, and cosmetic procedures to those wanting lifelong healthy skin.

Quthero Welcomes Dr. Omar Ibrahimi as Chief Medical Director

Retrieved on: 
Tuesday, April 2, 2024
Mohs surgery, Regeneration, Trust, Bruise, Patient, Harvard University, American Academy, Red, Laser, Doctor of Philosophy, MD, American College, Regenerative medicine, Society, Skin, Scar, Physician

TORONTO, April 2, 2024 /PRNewswire/ -- Quthero, a pioneering biotech company renowned for its unique Q-peptide platform technology, welcomes Omar Ibrahimi, MD, PhD, a world-renowned dermatologist, to the Quthero team as their Chief Medical Director.

Key Points: 
  • TORONTO, April 2, 2024 /PRNewswire/ -- Quthero, a pioneering biotech company renowned for its unique Q-peptide platform technology, welcomes Omar Ibrahimi, MD, PhD, a world-renowned dermatologist, to the Quthero team as their Chief Medical Director.
  • Quthero proudly announces that renowned dermatologist, Dr. Omar Ibrahimi, joins the team as Chief Medical Director.
  • Dr. Ibrahimi, a Harvard-trained, board-certified dermatologist, is the founder and medical director of the Connecticut Skin Institute with over 20 years of experience.
  • "It is a privilege and a great honor to have Dr. Ibrahimi join Quthero to lead the launch of Quthero's post-procedure products as a Chief Medical Director.

SleepOvation and SleepOvation Baby Announce Rebrand to Kiwi Sleep

Retrieved on: 
Tuesday, March 12, 2024
Bump, Health, Head, Growth, NAPPA, Social media, POPSUGAR, Parent, Safety, Bruise, Breathability, FDA, Pharmaceutical industry

WHARTON, N.J., March 12, 2024 /PRNewswire/ -- SleepOvation and SleepOvation Baby, known for innovative, research-based, FDA-listed sleep products including mattresses and pillows for babies, children and adults, is poised to unveil its rebranding effort under the new collective brand identity Kiwi Sleep. The initiative, which includes a refreshed, unified visual identity, updated website and social media platforms, represents the brand's next stage of growth and its continued mission to support a restorative, safe and pain-free sleep experience for the whole family.

Key Points: 
  • WHARTON, N.J., March 12, 2024 /PRNewswire/ -- SleepOvation and SleepOvation Baby, known for innovative, research-based, FDA-listed sleep products including mattresses and pillows for babies, children and adults, is poised to unveil its rebranding effort under the new collective brand identity Kiwi Sleep .
  • Its refreshed name, Kiwi Sleep, is anchored by the kiwi fruit and its proven health, wellness and sleep benefits, as well as its playful and vibrant attributes.
  • Under the new Kiwi Sleep brand name and tagline "Dreams Start Here," the identity refresh includes new logos and submarks, friendly typography, and a tranquil kiwi, cream and turquoise color palette.
  • To learn more about Kiwi Sleep and its product line, visit www.kiwisleep.com or connect on Instagram, Facebook and TikTok @kiwisleep.

10xBio Announces Data from Interim Analysis of Phase 2b Clinical Trial Showing Superior Efficacy of Novel Drug for Submental Body Contouring

Retrieved on: 
Monday, March 11, 2024
CSFS, PSFS, Biotechnology, Elective surgery, Bruise, Patient, SAN, Abdomen, American Academy, MD, Clinician, Clinical trial, American Academy of Dermatology, Erythema, ITT, FAAD, Pain, AAD, FDA, Organic acid, Edema, Annual general meeting, Pharmaceutical industry

SAN DIEGO, March 11, 2024 /PRNewswire/ -- 10xBio, LLC, a biotechnology company that focuses on new uses for existing therapies and technologies, announced today promising initial clinical trial results on its novel injectable drug for submental body contouring, 10XB101. An innovative alternative to other fat removal options, 10XB101 provides superior efficacy, fewer side effects, enhanced patient tolerability and shorter treatment intervals.

Key Points: 
  • SAN DIEGO, March 11, 2024 /PRNewswire/ -- 10xBio , LLC, a biotechnology company that focuses on new uses for existing therapies and technologies, announced today promising initial clinical trial results on its novel injectable drug for submental body contouring, 10XB101.
  • An innovative alternative to other fat removal options, 10XB101 provides superior efficacy, fewer side effects, enhanced patient tolerability and shorter treatment intervals.
  • "10XB101 has the appropriate product-market fit to capture the tremendous opportunity for submental contouring.
  • In addition, its attributes hold promise for potential expansion to other body contouring applications, such as treatment of the abdomen and flanks."

Stop & Shop Fights Pediatric Cancer with Kick Off of ‘Help Cure Childhood Cancer’ Campaign

Retrieved on: 
Thursday, February 29, 2024
Breast cancer, Hospital, Acute lymphoblastic leukemia, MSK, Bruise, Doctor of Philosophy, MD, The Jimmy Fund, Physician, Malignancy, Friends, Cancer, Parent, Skin, Hope, Stop & Shop, EMPOWER, T-cell acute lymphoblastic leukemia, Dana–Farber Cancer Institute, Radiation, Mouth, Stop, Health, Kidney cancer, Adolescence, COVID-19, Wilms' tumor, Leukemia, Young adult, Patient, Family, Pediatrics, Child, Rhabdomyosarcoma, Estate (law), Research, Cheek

Stop & Shop’s ‘Help Cure Childhood Cancer’ campaign will run in all stores from March 1 through March 31.

Key Points: 
  • Stop & Shop’s ‘Help Cure Childhood Cancer’ campaign will run in all stores from March 1 through March 31.
  • 100% of proceeds will benefit the two hospitals to assist in their pioneering pediatric cancer treatment and care.
  • The Stop & Shop Pediatric Brain Tumor Clinic at Dana-Farber Cancer Institute is a world-renowned destination for children with malignant and non-malignant brain tumors.
  • “Stop & Shop’s dedication and generous support of pediatric cancer continues to help fund critical research and care,” said Scott Armstrong, MD, PhD, chair of the Department of Pediatric Oncology at Dana-Farber Cancer Institute.